Biocon is a integrated healthcare company that delivers innovative biopharmaceutical solutions. From discovery to development and commercialisation, we have the defining science, cost-effective drug development capabilities and significant manufacturing capacity to move ideas to market.
Leveraging India’s globally competitive cost base and exceptional scientific people resource, we are advancing our in-house R&D programs, while also providing custom and clinical research services to international pharmaceutical and biotechnology majors through our subsidiary companies, Syngene and Clinigene.
Biocon has rapidly developed a robust drug pipeline, led by monoclonal antibodies and several other molecules at exciting stages in the biopharmaceutical value chain. With the successful commercial launch of our first anti-cancer drug and several promising discovery partnerships in the clinic, we remain committed to scaling new heights in frontier science and achieving new milestones in affordable medicine.
Biocon’s impressive range of products and partnered services continue to build a robust pipeline of biosimilar and discovery-led biologicals programs in oncology, nephrology, diabetes and autoimmune diseases.